Please assess the completion status of the following clinical trial:

Trial Title: Metformin in Co-morbid Diabetes or Prediabetes and Serious Mental Illness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients within 5 years of diagnosis of schizophrenia, schizoaffective disorder , or bipolar disorder(DSM V), or those younger than 40 years old, regardless of duration of illness~* Co-morbid diagnosis of prediabetes or diabetes (Canadian or American Diabetes Association criteria)~Exclusion Criteria:~* Patients with co-morbid axis, other than nicotine dependence, or cannabis abuse~* Patients with liver, or renal dysfunction,~* Patients with a positive drug urine screen (other than cannabis or nicotine)~* Females with a positive pregnancy test will be excluded.~* Prior trial with metformin, and reported lack of tolerability~* Patients with an A1C \> 9.5%, or symptomatic hyperglycemia with metabolic decompensation

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Metformin (Type: PLACEBO_COMPARATOR): Metformin/ placebo will be dispensed on a biweekly basis, and pill counts conducted at each visit.
- Placebo (Type: PLACEBO_COMPARATOR): Metformin/ placebo will be dispensed on a biweekly basis, and pill counts conducted at each visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).